企业QQ
官方微信
普华量宇荣幸的宣布与美国Acousys Biodevices Inc(ABI)签署产品独家代理协议。双方一致同意该协议的签署会带来双赢的结果。
美国Acousys Biodevices Inc(ABI)是循环肿瘤细胞（Circulating Tumor Cells,CTCs)计数与分选的创新者。独家专利的光声检测及时应用于循环肿瘤细胞的研究领域，该技术有望成为未来改变游戏规则者。具体的发布信息参考原文如下：
Acousys Biodevices Inc (ABI) Inks Exclusive Distributor Agreement with Uniquantus, for Commercialization in China of its Products for Detection and Capture of Circulating Tumor Cells (CTCs)
September 1, 2014, Pittsburgh, PA; Acousys Biodevices Inc, a leading innovator and producer of products for detection and automated capture of CTCs, is pleased to announce the signing of an exclusive distributorship agreement with Uniquantus, for commercialization of its Circulating Tumor Cell System CTCS 3.0, and CTC assay kits in China. This new strategic alliance will serve the needs of a rapidly growing customer base in China, and significantly expand distribution of Acousys products into that new market. Through this agreement, ABI is gaining an experienced partner, with the network, resources, and support services required for successful commercialization of its products in the Chinese market.
Dr. Martin Sanders, Acousys Biodevices’ Executive Chairman commented, “The signing of this distributorship agreement is an important advance for Acousys, in that it is the first expansion of the company’s commercialization of its products to a market outside the U.S. I am very pleased that the company has established this relationship with Uniquantus for commercialization of its products in China, and believe that this relationship will provide a template and springboard for expansion of the commercialization of the company’s products into multiple international markets.”
This new release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.